Journal Article

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Sadik, Christian D., Olbrich, Henning, Ludwig, Ralf J., Boch, Katharina, Thaçi, Diamant

2023

Overview

Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

• Publisher: MDPI AG,MDPI
• Subject: Allergens / Allergies / alopecia areata / Antibodies, Monoclonal, Humanized - therapeutic use / Asthma / Atopic dermatitis / Autoimmune diseases / Case reports / Clinical trials / Dermatitis / Dermatitis, Atopic - drug therapy / Dermatology / Drug therapy / dupilumab / Eczema / FDA approval / Humans / Inflammation / Light therapy / Monoclonal antibodies / Netherton syndrome / Patients / Prurigo - drug therapy / prurigo nodularis / Pruritus / Quality of life / review / Skin / Skin diseases / Steroids / Systematic Review / Urticaria